Literature DB >> 33238738

Role of comorbidities in heart failure prognosis Part I: Anaemia, iron deficiency, diabetes, atrial fibrillation.

Stefania Paolillo1, Angela B Scardovi2, Jeness Campodonico3.   

Abstract

Cardiovascular and non-cardiovascular comorbidities are frequently observed in heart failure patients, complicating the therapeutic management and leading to poor prognosis. The prompt recognition of associated comorbid conditions is of great importance to optimize the clinical management, the follow-up, and the treatment of patients affected by chronic heart failure. Anaemia and iron deficiency are commonly reported in all heart failure forms, have a multifactorial aetiology and are responsible for reduced exercise tolerance, impaired quality of life, and poor long-term prognosis. Diabetes mellitus is highly prevalent in heart failure and a poor glycaemic control is associated with worst outcome. Two specific heart failure forms are usually observed in diabetic patients: an ischaemic cardiomyopathy or a typical diabetic cardiomyopathy. The implementation of use of sodium-glucose cotransporter-2 inhibitors will much improve in the near future the long-term prognosis of patients affected by heart failure and diabetes. Among cardiovascular comorbidities, atrial fibrillation is the most common arrhythmic disease of heart failure patients and it is still not clear whether its presence should be considered as a prognostic indicator or as a marker of advanced disease. The aim of the present review was to explore the clinical and prognostic impact of anaemia and iron deficiency, diabetes mellitus, and atrial fibrillation in patients affected by chronic heart failure.

Entities:  

Keywords:  Heart failure; anaemia; atrial fibrillation; diabetes mellitus; iron deficiency

Mesh:

Substances:

Year:  2020        PMID: 33238738      PMCID: PMC7691628          DOI: 10.1177/2047487320960288

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  42 in total

1.  Deceptive meaning of oxygen uptake measured at the anaerobic threshold in patients with systolic heart failure and atrial fibrillation.

Authors:  Damiano Magrì; Piergiuseppe Agostoni; Ugo Corrà; Claudio Passino; Domenico Scrutinio; Pasquale Perrone-Filardi; Michele Correale; Gaia Cattadori; Marco Metra; Davide Girola; Massimo F Piepoli; AnnaMaria Iorio; Michele Emdin; Rosa Raimondo; Federica Re; Mariantonietta Cicoira; Romualdo Belardinelli; Marco Guazzi; Giuseppe Limongelli; Francesco Clemenza; Gianfranco Parati; Maria Frigerio; Matteo Casenghi; Angela B Scardovi; Alessandro Ferraironi; Andrea Di Lenarda; Maurizio Bussotti; Anna Apostolo; Stefania Paolillo; Rocco La Gioia; Paola Gargiulo; Pietro Palermo; Chiara Minà; Stefania Farina; Elisa Battaia; Antonello Maruotti; Giuseppe Pacileo; Mauro Contini; Fabrizio Oliva; Roberto Ricci; Gianfranco Sinagra
Journal:  Eur J Prev Cardiol       Date:  2014-09-26       Impact factor: 7.804

2.  Long-term mortality is increased in patients with undetected prediabetes and type-2 diabetes hospitalized for worsening heart failure and reduced ejection fraction.

Authors:  Andrija Pavlović; Marija Polovina; Arsen Ristić; Jelena P Seferović; Ivana Veljić; Dejan Simeunović; Ivan Milinković; Gordana Krljanac; Milika Ašanin; Irena Oštrić-Pavlović; Petar M Seferović
Journal:  Eur J Prev Cardiol       Date:  2018-10-18       Impact factor: 7.804

Review 3.  Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure.

Authors:  Michele Correale; Stefania Paolillo; Valentina Mercurio; Giuseppe Limongelli; Francesco Barillà; Gaetano Ruocco; Alberto Palazzuoli; Domenico Scrutinio; Rocco Lagioia; Carolina Lombardi; Laura Lupi; Damiano Magrì; Daniele Masarone; Giuseppe Pacileo; Pietro Scicchitano; Marco Matteo Ciccone; Gianfranco Parati; Carlo G Tocchetti; Savina Nodari
Journal:  Eur J Intern Med       Date:  2019-11-08       Impact factor: 4.487

4.  Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure.

Authors:  Ewa A Jankowska; Piotr Rozentryt; Agnieszka Witkowska; Jolanta Nowak; Oliver Hartmann; Beata Ponikowska; Ludmila Borodulin-Nadzieja; Stephan von Haehling; Wolfram Doehner; Waldemar Banasiak; Lech Polonski; Gerasimos Filippatos; Stefan D Anker; Piotr Ponikowski
Journal:  J Card Fail       Date:  2011-11       Impact factor: 5.712

Review 5.  Anemia and Iron Deficiency in Heart Failure: Clinical and Prognostic Role.

Authors:  Damiano Magrì; Fabiana De Martino; Federica Moscucci; Piergiuseppe Agostoni; Susanna Sciomer
Journal:  Heart Fail Clin       Date:  2019-04-05       Impact factor: 3.179

6.  Prognostic role of atrial fibrillation in patients affected by chronic heart failure. Data from the MECKI score research group.

Authors:  Stefania Paolillo; Piergiuseppe Agostoni; Daniele Masarone; Ugo Corrà; Claudio Passino; Domenico Scrutinio; Michele Correale; Gaia Cattadori; Marco Metra; Davide Girola; Massimo F Piepoli; Elisabetta Salvioni; Marta Giovannardi; Annamaria Iorio; Michele Emdin; Rosa Raimondo; Federica Re; Mariantonietta Cicoira; Romualdo Belardinelli; Marco Guazzi; Francesco Clemenza; Gianfranco Parati; Angela B Scardovi; Andrea Di Lenarda; Rocco La Gioia; Maria Frigerio; Carlo Lombardi; Paola Gargiulo; Gianfranco Sinagra; Giuseppe Pacileo; Pasquale Perrone-Filardi; Giuseppe Limongelli
Journal:  Eur J Intern Med       Date:  2015-05-27       Impact factor: 4.487

7.  Permanent atrial fibrillation affects exercise capacity in chronic heart failure patients.

Authors:  Piergiuseppe Agostoni; Michele Emdin; Ugo Corrà; Fabrizio Veglia; Damiano Magrì; Calogero C Tedesco; Emanuela Berton; Claudio Passino; Erika Bertella; Federica Re; Alessandro Mezzani; Romualdo Belardinelli; Chiara Colombo; Rocco La Gioia; Marco Vicenzi; Alberto Giannoni; Domenico Scrutinio; Pantaleo Giannuzzi; Claudio Tondo; Andrea Di Lenarda; Gianfranco Sinagra; Massimo F Piepoli; Marco Guazzi
Journal:  Eur Heart J       Date:  2008-08-05       Impact factor: 29.983

Review 8.  Anemia and mortality in heart failure patients a systematic review and meta-analysis.

Authors:  Hessel F Groenveld; James L Januzzi; Kevin Damman; Jan van Wijngaarden; Hans L Hillege; Dirk J van Veldhuisen; Peter van der Meer
Journal:  J Am Coll Cardiol       Date:  2008-09-02       Impact factor: 24.094

9.  A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).

Authors:  John J V McMurray; David L DeMets; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Anna M Langkilde; Felipe A Martinez; Olof Bengtsson; Piotr Ponikowski; Marc S Sabatine; Mikaela Sjöstrand; Scott D Solomon
Journal:  Eur J Heart Fail       Date:  2019-03-21       Impact factor: 15.534

10.  Opportunistic screening models for high-risk men and women to detect diastolic dysfunction and heart failure with preserved ejection fraction in the community.

Authors:  Aisha Gohar; Rogier F Kievit; Gideon B Valstar; Arno W Hoes; Evelien E Van Riet; Yvonne van Mourik; Loes C Bertens; Leandra J Boonman-Winter; Michiel L Bots; Hester M Den Ruijter; Frans H Rutten
Journal:  Eur J Prev Cardiol       Date:  2018-11-27       Impact factor: 7.804

View more
  4 in total

1.  Adiponectin ameliorates placental injury in gestational diabetes mice by correcting fatty acid oxidation/peroxide imbalance-induced ferroptosis via restoration of CPT-1 activity.

Authors:  Yifang Zheng; Qiaosheng Hu; Jieli Wu
Journal:  Endocrine       Date:  2021-12-02       Impact factor: 3.633

2.  Predictive value of overt and non-overt volume overload in patients with high- or low-gradient aortic stenosis undergoing transcatheter aortic valve implantation.

Authors:  Ulrich Fischer-Rasokat; Matthias Renker; Christoph Liebetrau; Maren Weferling; Andreas Rieth; Andreas Rolf; Yeong-Hoon Choi; Christian W Hamm; Won-Keun Kim
Journal:  Cardiovasc Diagn Ther       Date:  2021-10

Review 3.  Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction: Pathophysiology, Assessment, Prevalence and Prognosis.

Authors:  Joanna M Bilak; Uazman Alam; Christopher A Miller; Gerry P McCann; Jayanth R Arnold; Prathap Kanagala
Journal:  Card Fail Rev       Date:  2022-07-01

Review 4.  Putative protective effects of sodium-glucose cotransporter 2 inhibitors on atrial fibrillation through risk factor modulation and off-target actions: potential mechanisms and future directions.

Authors:  Syona S Shetty; Andrew Krumerman
Journal:  Cardiovasc Diabetol       Date:  2022-06-28       Impact factor: 8.949

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.